Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy [Seeking Alpha]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Seeking Alpha
Follow Summary Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market. Investors should consider potential risks and wait for market stabilization post-fundraising, but the long-term upside remains compelling with possible +75% upside in play, in my view. There are some risks to consider - length of time to potential approval the most prominent - but it's rare to see such a compelling data set when market incumbents are so established. MicroStockHub/iStock via Getty Images Investment Overview - Background To Recent Explosive Share Price Growth Foster City, California based Vaxcyte ( NASDAQ: PCV
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- Vaxcyte, Inc. (NASDAQ: PCVX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $140.00 price target on the stock.MarketBeat
- Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
PCVX
Earnings
- 11/5/24 - Beat
PCVX
Sec Filings
- 11/8/24 - Form 4
- 11/8/24 - Form 4
- 11/8/24 - Form 4
- PCVX's page on the SEC website